HLC: Congress Should Disregard ‘Flawed’ MedPAC Analysis Of MA Costs

By Amy Lotven / September 18, 2025 at 3:54 PM

The Healthcare Leadership Council is urging policymakers to cast aside congressional Medicare advisors’ analysis of Medicare Advantage costs, arguing that MedPACs recently revised methodology is flawed as it fails to consider the value of MA, skews estimates of coding intensity and favorable selection, and dramatically inflates payments for MA.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.